Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLAR phase 3 open-label study of salanersen in adolescents and adults with spinal muscular atrophy
jRCT2051260160Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Nov 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of salanersen in spinal muscular atrophy (SMA) (2 cohorts), sponsored by Biogen. Primary endpoint: Change from baseline in Hammersmith Functional Motor Scale - Expanded total score in treatment-naive cohort. Started Nov 2026; status: recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on jRCT2051260160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260160.